WebNov 1, 2024 · FDA has granted the toripalimab BLA Priority Review with a target action date of April 2024. SHANGHAI, China and REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences ... WebMar 24, 2024 · Although toripalimab is currently the cheapest compared with other PD-(L)1 inhibitors, its economics are not clear. Therefore, this study aimed to evaluate the cost-effectiveness of toripalimab coupled with chemotherapy in the treatment of NSCLC from the perspective of the Chinese healthcare system. 2. Materials and methods 2.1. Model …
Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant
WebMar 24, 2024 · Background and objective: The CHOICE-01 trial showed that toripalimab plus chemotherapy achieved satisfactory outcomes compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) who were negative for driver genes, but the economics of this regimen is unclear. Therefore, this study aimed to evaluate the … WebMar 3, 2024 · Tuoyi (toripalimab) – 906.80 yuan/ bottle (80 mg/2 mL) – 1,074.87 yuan/bottle (100 mg/2.5 mL) – 2,100.97 yuan/bottle (240 mg/6 mL) – 54,900 yuan annual treatment cost (70+% discount) – Unresectable or converted patients with previously failed systemic treatment of metastatic melanoma: March 1, 2024 to December 31, 2024: … figure eight scale on a globe
Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and ...
WebFeb 3, 2024 · Introduction: Immune checkpoint inhibitors (ICIs) are effective in the treatment of advanced esophageal squamous cell carcinoma (ESCC); however, their efficacy in locally advanced resectable ESCC and the potential predictive biomarkers have limited data. Methods: In this study, locally advanced resectable ESCC patients were enrolled and … WebHowever, little is known about the actual financial burden (actual price, adverse events, post-progression treatment) it represents and its cost-effectiveness. Recent data from the field of hepatocellular carcinoma compared pembrolizumab to placebo as a second-line treatment showed an incremental 0.153 life-year benefit for the anti-PD-1 agent ... WebFeb 17, 2024 · Conclusion In our analysis, compared with GP chemotherapy alone, toripalimab plus GP was more cost-effective, while camrelizumab plus GP … figure eight roller coaster